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Abstract
Minimizing perioperative blood loss during orthopedic surgery has proven challenging for
providers. Perioperative utilization of antifibrinolytic pharmacologic interventions, such as
tranexamic acid (TXA), has been demonstrated as a safe and effective technique for decreasing
blood loss and allogenic blood transfusion rates. Currently, the Food and Drug Administration
(FDA) approved on-label indications of TXA are for use in short-term treatment of hemophilia
patients undergoing dental extractions and in management of patients experiencing menorrhagia
(Mayeux, Alwon, Collins, & Hewer, 2016). Despite the current limited scope of FDA approval
for TXA, use in elective surgery with otherwise clotting-uncompromised patients is not a new
concept. Perioperative TXA administration in elective joint replacement surgery,
cardiopulmonary bypass, spinal fusions, and hysterectomies has been well studied (Duncan et al.,
2015). Numerous studies have acknowledged TXA use decreases perioperative blood loss,
decreases perioperative blood transfusions, and shortens length of hospital stay. Additionally,
research exists that demonstrates safety and efficacy of TXA use in patients presenting with
traumatic injury (Roberts et al., 2013). Despite this vast body of knowledge, little research exists
evaluating TXA use in hip fractures. Over 325,000 traumatic hip fractures occur every year
(Neuman, Rosenbaum, Ludwig, Zubizarreta, & Silber, 2014). This patient population is
generally frail and typically lacks optimization prior to urgent surgery. Based on the extensive
body of prior research conducted to date, it is reasonable to postulate that TXA use in these
instances would yield a decreased blood loss and therefore contribute to lower rates of allogenic
blood transfusion in hip fracture patients.
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Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures
Introduction
Finding new and innovative methodologies to reduce surgical blood loss is a major area
of interest among orthopedic surgeons. Over the past two decades a variety of techniques
ranging from blood salvage systems to pharmacologic approaches have been examined as means
to accomplish this goal and reduce the number of allogenic blood transfusions required during
and after orthopedic surgical procedures. In recent years, employment of pharmacologic
methods has become increasingly popular. Specifically, administration of an antifibrinolytic
agent during the perioperative period has been proven to be an effective means of decreasing
intraoperative bleeding. The reduction of intraoperative bleeding is expected to confer a benefit
to the patient by reducing the need for allogenic blood and blood product transfusions as well as
the sequale associated with such transfusions (Das, Vijay, Bedi, & Mitra, 2013). One
antifibrinolytic in particular, tranexamic acid (TXA), has been well studied for use in scheduled,
elective orthopedic surgery with heavy emphasis on total hip arthroplasty (THA) and total knee
arthroplasty (TKA) (Charoencholvanich & Siriwattanasakul, 2011). TXA is a lysine amino acid
derivative that prevents break down of the fibrin clot. TXA competitively binds to plasminogen.
This competitive binding action obstructs naturally occurring lysine from binding with
plasminogen thus preventing the formation of the enzyme plasmin. Inhibition of the conversion
of plasminogen to plasmin preserves the formed fibrin clot thereby decreasing blood loss at the
site of bleeding or injury via clot stabilization (Vijay, Bedi, Mitra, & Das, 2013).
Despite the over 325,000 hip fractures currently occurring each year in the United States
and with hip fracture rates projected to increase each year reaching an estimated 500,000 per
year in 2040 (Neuman, Rosenbaum, Ludwig, Zubizarreta, & Silber, 2014), research examining
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the efficacy of utilizing TXA in hip fracture surgery is quite limited. Recent studies have
generally been conducted on a relatively smaller scale and been limited to scheduled, elective
procedures. The focus of these studies has centered primarily on the ability of TXA
administration to reduce overall blood loss, examination of the incidence of adverse thrombolic
vascular occlusive events associated with the administration of TXA, or both. In
supplementation to these findings, The CRASH-2 Trial: A Randomized Controlled Trial and
Economic Evaluation of the Effects of Tranexamic Acid on Death, Vascular Occlusive Events
and Transfusion Requirement in Bleeding Trauma Patients (CRASH-2) study by Roberts et al.
(2013), reviewed later in this paper, provides high quality evidence suggestive of both the safety
and efficacy of TXA use in patients presenting with traumatically sustained injuries and
otherwise normal coagulation profiles.
While there is substantial high quality evidence supporting both the safety and efficacy of
TXA use to reduce overall blood loss and need for allogenic blood transfusions during both
scheduled orthopedic joint procedures as well as traumas, a limited quantity of research exists in
support of administration of TXA to traumatic hip fracture patients (Roberts et al., 2013). These
patients are not optimized for surgery and are therefore considered fragile and potentially more
vulnerable during the postoperative period. Administration of an antifibrinolytic agent to reduce
blood loss in patients who have sustained traumatic hip injuries has the potential to greatly
improve patient outcomes.
This lack of high quality peer reviewed evidence prompted the organization of such a
research study to be conducted at Central Maine Medical Center (CMMC). Central Maine
Medical Center is located at 300 Main Street in Lewiston, Maine. The hospital serves most of
Androscoggin County, Maine and various small and medium-sized communities (Central Maine
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Medical Center, n.d.). CMMC is a 300-bed, Level-II trauma center which preforms over 9,000
surgeries annually (Central Maine Medical Center, n.d.). CMMC is a teaching affiliate of
Boston University School of Medicine as well as University of New England College of
Osteopathic Medicine (Central Maine Medical Center, n.d.).
Currently, a research proposal (please see Appendix A for the entire proposal) has been
created, submitted to, and approved by the IRB at CMMC (please see Appendix E for approval
letter). This paper will examine the literature reviewed to construct the proposal, an outline of
the study methods and goals, as well as a progress update. All materials generated for
submission to the IRB, IRB applications, patient handouts, informed consent literature, and
approval documentation are attached in the appendices of this paper (Appendix B, C, and D).
Literature Review
TXA is a lysine amino acid derivative that aids in the prevention of the break down of
existing clots. TXA competitively binds to plasminogen preventing the formation of the enzyme
plasmin. By blocking the conversion of plasminogen to plasmin, the fibrin clot is stabilized and
continues to exist thus decreasing the amount of blood lost at the site of injury or surgical
incision (Napolitano, Cohen, Cotton, Schreiber, & Moore, 2013). Currently, TXA is only
approved by the US Food and Drug Administration (FDA) in oral short term use for patients
with hemophilia needing dental surgery and for the treatment of menorrhagia (Mayeux, Alwon,
Collins, & Hewer, 2016). However, antifibrinolytics are actively being used off label in multiple
types of surgery including cardiopulmonary bypass, elective total joint replacements, ear, nose,
and throat (ENT), and spinal fusions.
Because TXA disrupts the normal process of clot dissolution, safety questions around its
use regarding a potential increase in the incidence of thromboembolic events have emerged.
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Consideration of patient safety is of paramount concern when proposing or initiating research on
human subjects. Initial research results examined discussed the potential for increased adverse
vascular occlusive events that may be associated with TXA administration to patients with an
intact clotting profile. The largest of these studies was The CRASH-2 Trial: A Randomized
Controlled Trial and Economic Evaluation of the Effects of Tranexamic Acid on Death, Vascular
Occlusive Events and Transfusion Requirement in Bleeding Trauma Patients (CRASH-2) study
conducted by Roberts et al. (2013). This level I evidence, multicenter, randomized, placebocontrolled study examined the administration of TXA to “adult trauma patients with or at
significant risk for bleeding and were within eight hours of injury undergoing surgical
intervention to address their injuries and/or cause of bleeding” (Roberts et al., 2013, p. 1). In this
study 10,096 adult trauma patients were administered a one gram loading dose of TXA over 10
minutes and started on an infusion of one gram of TXA over eight hours within eight hours of
sustaining their traumatic injury. For control comparison, 10,115 patients were administered
normal saline in the same manner. As previously stated, CRASH-2 is one of the largest studies
conducted to date examining the potential effects of TXA administration. CRASH-2 assessed
the use of TXA in trauma patients with the goal of reducing death rates due to uncontrolled
bleeding. Results from CRASH-2 showed a significant decrease in bleeding following trauma
and ultimately determined that the administration of TXA to trauma patients yielded a decrease
in the observed death rate. The mortality rate observed in the TXA group was 4.8% compared to
6.1% in the placebo group. Additionally, CRASH-2 revealed that TXA safely decreased the risk
of death without increasing the risk of vascular events. The rate of a vascular occlusion, such as
a myocardial infarction, deep vein thrombosis, or pulmonary embolism, was 1.7% for patients
that received TXA and 2% for those who received the placebo (Roberts et al, 2013).
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Ultimately, this study concluded that administration of TXA within three hours of
initial injury “safely reduced the risk of death in bleeding trauma patients and (TXA) is highly
cost-effective” (Roberts et al., 2013, p. 1). Furthermore, CRASH-2 helped establish TXA as an
essential medication on the World Health Organization’s (WHO) list. The WHO list of essential
medications declares certain medications should be available in ample amounts at affordable
pricing due to their proven safety and efficacy as demonstrated by use with positive outcomes on
a large number of patients (Roberts et al., 2013).
Duncan et al. (2015) conducted a single center retrospective cohort study demonstrating
the safety of TXA administration to patients with normal coagulation profiles. Individual
orthopedic surgeons within the institution had been using TXA on a patient-by-patient basis
when they determined a potential benefit was present. The orthopedic department on the whole
came to the conclusion TXA offered a benefit to the majority of the patients undergoing joint
surgeries. A protocol for its routine use was established. The institution sought positive
affirmation that TXA was a safe and effective means to reduce bleeding during scheduled
orthopedic procedures and approved the study proposed by Duncan et al. (2015). Patients
included in this study were undergoing either an elective THA or TKA. Patient data over a 5year period was collected, collated, and examined to determine if administration of TXA
contributed to an increased incidence of untoward vascular occlusive events. Duncan et al.
(2015) concluded “the overall frequency of clinically significant (venous thromboembolism)
VTE was lower when TXA was administered, and the odds of postoperative VTE were
unchanged” (Duncan et al., 2015, p. 275). As additional positive support to the primary study
finding, the authors noted “no statistically significant change was seen in 30-day mortality,
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although a trend toward reduced mortality with TXA administration was observed” (Duncan et
al., 2015, p. 275).
Having found evidence in support of the safety of TXA use in both scheduled as well as
trauma surgeries, the search expanded to examine current evidence attesting to the efficacy of
perioperative TXA administration. One such study consisted of a large meta-analysis looking at
amicar, tranexamic acid, and aprotinin (Zufferey et al., 2006). No significant increase in
thromboembolic events stemming from the use of these three antifibrinolytic therapies was found
during this study. These results serve to corroborate the safety of administration of
antifibrinolytic agents during surgical procedures reported by other studies. Additionally, all
three antifibrinolytics showed a decrease in the amount of surgical blood loss and there was a
concomitant decrease in the rate of allogenic blood transfusions required in the postoperative
period. Zufferey et al. (2006) found that aprotinin and tranexamic acid specifically decrease
blood loss and blood transfusion rates when administered during the perioperative period in
orthopedic surgery.
Vijay, Bedi, Mitra and Das (2013) examined the ability of TXA to reduce perioperative
blood loss during scheduled orthopedic procedures. They focused their study solely on the use
of TXA in patients undergoing hip fracture surgery. Patients were either a physical classification
status I or II between the ages of 18 and 80. Of the 90 participants in this study, 45 were
randomized into the test group and received TXA while 45 were randomized into the control
group and did not receive TXA. Primary outcomes for this study included examination of the
volume of blood in the patients surgical site drain postoperatively, percentage of hemoglobin fall
on postoperative day zero and day two, and allogenic blood transfusion rates. The blood volume
output into the surgical site drains for the TXA group was 39.33 +/- 10.09 mL compared to 91.11
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+/- 17.61 mL in the control group. Hemoglobin drop in the TXA on day zero was 2.99 +/- 3.45
mL compared to the control group of 7.70 +/- 6.05 mL. On postoperative day two, TXA
hemoglobin drop was 0.35 +/- 0.74 g/dL and the control group was 2.72 +/- 2.7 g/dL. Eighteen
of the 45 patients in the control group received an allogenic blood transfusion while only seven
out of 45 patients in the TXA group required transfusion (Vijay et al., 2013). The level I
evidence presented by Vijay et al. (2013) demonstrated the ability of TXA administration in the
perioperative period to be an effective means to reduce postoperative blood loss and realize a
reduced transfusion requirement for patients during major hip surgeries.
In a 2011 Cochrane Review, the safety and efficacy of TXA was addressed (Henry et al.,
2011). A placebo was compared to TXA when examining the rate of allogenic blood
transfusions and adverse vascular events. A total of 4,842 patients were randomized into either
the placebo/control group or the TXA group. Patients who received TXA saw a reduction in the
rate of allogenic blood transfusions by 39%. There was no increased risk of patients
experiencing a thromboembolic event including stroke, deep vein thrombosis, myocardial
infarction, pulmonary embolism, or development of renal disease reported in this study. Henry
et al. (2011) also showed there was no correlation between an increase in mortality and the use of
TXA.
Pongcharoen and Ruetiwarangkoon (2015) made conclusions similar to Duncan et al.
(2015). In their paper, a prospective controlled study was performed to examine the total amount
of surgical blood loss experienced as well as the incidences of adverse vascular occlusive events
experienced by their study participants. Patients in this study were followed for a minimum of
12 months in an effort to determine if the potential for delayed untoward vascular events existed.
While patients in the TXA group of this study were found to have experienced lower amounts of
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intraoperative blood loss, this result was not statistically significantly. More germane to the
context of the research being conducted at Central Maine Medical Center, this level I evidence
study demonstrated that patients in both the TXA group as well as the control group “did not
present the clinical signs of (deep venous thrombosis) DVT and (pulmonary embolism) PE.
They also did not show other thromboembolic events including cerebral vascular accidents or
myocardial infarctions” (Pongcharoen & Ruetiwarangkoon, 2016, p. 7). This study continues to
support the safety profile of TXA use in patients with uncompromised coagulation profiles.
Numerous level I, II, and one level III quality of evidence studies have examined the
concomitant reduction of blood loss and safety of TXA administration to patients undergoing
orthopedic procedures. Poeran et al. (2014) conducted a retrospective cohort study of 510
hospitals in the United States looking at patients undergoing elective TKA or THA. Patients
were grouped into those who received TXA in any form or dose versus those that did not.
Poeran et al. (2014) found that TXA was an effective pharmacological intervention for the
reduction in the need for allogenic blood transfusions while it did not produce an increased risk
for adverse vascular complications in patients receiving the drug.
Hart et al. (2014) examined the incidence of transfusion rates for over 23,000 patients
that received either a total knee arthroplasty or a total hip arthroplasty. Patients in this study did
not receive an antifibrinolytic agent of any kind. Allogenic blood transfusion rates were found to
be as high as 22% for total hip arthroplasty and 18.3% for total knee arthroplasty (Hart et al.,
2014). Transfusion rates were deemed high given the number of patients in this study.
Additionally, Hart et al. (2014) determined the mortality rate was increased in those patients who
did receive a transfusion. Due in part to these findings as well as countless others like it,
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administration of TXA in elective joint replacement surgery has now become routine due to the
high incidence of allogenic transfusion rates.
In a randomized, double blind study involving 99 patients timing of TXA administration
in total knee arthroplasty patients was examined (Tanaka et al., 2001). Tanaka et al. (2001)
sought to determine the time for TXA administration that would achieve the greatest reduction in
blood loss. They determined that administration prior to incision and again once the tourniquet
was deflated showed the greatest reduction in perioperative blood loss. Regardless of the timing
of administration, Tanaka et al. (2001) indicated there was a 40% decrease in blood loss after the
administration of TXA. Additionally, there was no reported increase in thromboembolic events
observed during this study. These findings once again support the safety as well as the efficacy
of TXA administration.
Blood loss continues from the time of injury throughout the perioperative period. Blood
oozes from the ends of cut bone, open intra-medullary canals, and from soft tissue after
dissection (Sepah et al., 2011). Over a three-year period patients undergoing a total knee
arthroplasty were randomized into two groups: those who received TXA or those who received
a placebo. Postoperatively, recipients of TXA experienced a mean blood loss from their drain of
826-1,288 mLs whereas the placebo group experienced drainage of 1,828-2,695 mLs. Once
again, these findings present evidence that advocates for the use of TXA to decrease patient
blood loss during the perioperative period. None of the patients in the Sepah et al. (2011) study
experienced problematic vascular events from the use of TXA. This finding is supportive of the
safety of TXA.
One of the major motivating factors behind seeking methods to control perioperative
blood loss is the potential need for patients experiencing high levels of surgical blood loss to
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require allogenic blood transfusions during the perioperative period. Zhang, Chen, Chen, and
Que (2011) conducted a systematic literature review study examining 15 randomized control
studies encompassing 842 patient outcomes. Zhang et al. (2012) determined that administration
of TXA during the perioperative period reduced the total blood loss and reported that the risk of
transfusion was reduced by 56% due to the administration of TXA. Further, the use of TXA did
not yield an increase in the risk of deep vein thrombosis when administered to patients with an
intact clotting profile undergoing TKA (Zhang et al., 2012). Other similar studies also
considered the benefit of giving TXA to reduce perioperative bleeding during TKA and THA to
determine if a reduction in the number of perioperative allogenic blood product transfusion could
be achieved with positive outcomes. One retrospective quality of care chart review comparison
of data before vs. after implementation of a TXA administration protocol found that data
collected supported the perioperative administration of TXA due to its ability to reduce the
number of blood transfusions required while not increasing the number of observed adverse
vascular events (Baker et al., 2015). Baker et al. (2015) reported that as the utilization of TXA
increased from 45.8% to 95.3% in patients undergoing TKA the rate of allogenic transfusions
required in patients during the postoperative period was reduced from 8.8% to 5.2%. While
findings presented by Baker et al. (2015) is level III evidence, Gandhi, Evans, Mahomed, &
Mahomed (2013) presented level I evidence in support of utilization of TXA in the perioperative
period to realize a reduction in the number of postoperative allogenic blood transfusions.
Patients undergoing both THA as well as TKA were included in this Cochrane Review by
Gandhi et al. (2013). Specific interventions were very similar; all patients in the study test
groups were intravenously administered TXA in either variable doses ranging from 10-15 mg/kg
or 500-1,500 mg fixed doses prior to incision (Gandhi et al., 2013). Gandhi et al. (2013)
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demonstrated that the number of patients receiving allogenic transfusions was less in the TXA
groups when compared to the control groups. Additionally, there was no increase in the number
of patients developing deep vein thrombosis or other untoward thromboembolic complications in
the TXA groups as compared to the control groups. This study, once again, offered high quality
evidence supporting both the safety and efficacy of TXA in addition to its ability to realize a
statistically significant reduction in the number of allogenic blood product transfusions required
to be given to patients undergoing scheduled orthopedic joint procedures.
Lee, Freeman, Edmondson, & Rogers (2015) examined 305 patients who underwent a
total hip arthroplasty. In this study, the efficacy of TXA administration to decrease perioperative
blood loss and allogenic blood transfusions was examined. Lee et al. (2015) reported data on
over 300 patients who received a total hip arthroplasty and were randomized into either those
who received TXA or the control group who did not receive TXA. It was found that those who
received TXA experienced a lower transfusion rate. Transfusion rates were 6% in patients that
received TXA and 19% in patients that did not receive TXA. Hemoglobin was also measured
preoperatively and postoperatively in these patients. Postoperative hemoglobin dropped by 26%
in the patients that received TXA and 42% in the non-TXA control group. The patients that
received TXA exhibited a large reduction in both transfusion rates and overall drop in
hemoglobin level. Henry et al. (2015) estimated that the use of TXA prevents one blood
transfusion per every eight patients, thus supporting the routine use of TXA in orthopedic
surgery.
Charoencholvanich and Siriwattanosakul (2011) examined the duration of action of TXA.
They sought information about its ability to help decrease blood loss and blood transfusion rates
in the postoperative period. Therapeutic levels of TXA were detected in peripheral blood
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samples for up to eight hours following administration. This coincides with the duration of
hyperfibrinolysis that can last up to eight hours following any kind of injury or trauma.
Hyperfibrinolysis is an increased state of clot dissolution following disruption of normal
homeostasis. Homeostasis is disrupted as soon as injury occurs or surgical incision occurs.
Additionally, 65% of blood drainage happens in the first eight hours following surgery.
Charoencholvanich and Siriwattanosakul (2011) randomized 100 patients undergoing a total
knee arthroplasty into two groups. One group received a placebo and the second group received
a bolus of TXA. Both groups received standard treatment prior to incision and again after
deflation of the tourniquet. Postoperative drainage was estimated to be 1,208mLs +/- 421mLs in
the placebo group and 727mLs +/- 234mLs in the group that received TXA. The number of
patients requiring an allogenic blood transfusion was decreased by 56-90% with the
administration of TXA (Charoencholvanich & Siriwattanosakul, 2011). These findings again
support the use of TXA in orthopedic surgery to aid in decreasing the requirement for blood
product transfusions.
Administration of TXA is also being used in joint revision surgery, as these procedures
tend to have a greater blood loss due to increased manipulation during removal of the existing
hardware. After mobilization and removal of old hardware, new hardware then needs to be
placed, increasing the potential blood loss. Samujh, Falls, Wessel, Smith, & Malikani (2014)
examined TXA administration solely in total knee arthroplasty revisions. Their research found a
clinically significant decrease in allogenic blood transfusion rates in the patient group receiving
TXA. The control group in this study, as a whole, used 25 units of blood whereas the TXA
group required the use of only three units of blood. Also the transfusion rate reported in the
control group was 30.3% compared to 16.7% in the TXA receiving group. This clinically
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significant observed decrease in blood transfusion rate again supports the perioperative
administration of TXA. Untoward vascular events were documented in this study.
Thromboembolic events occurred in 3% of patients from the control group (2 out of 68 patients)
and 2% (1 out of 43 patients) of patients in the TXA group (Samujh et al, 2014). While an
unfortunate occurrence contributing to overall morbidity, the incidence of vascular events
reported was higher in the control group versus the TXA group suggesting it was not the
administration of TXA that contributed to the reported events.
Review of Dosing Strategies
Having found significant amounts of high quality evidence within the current body of
literature to support the safety of administration of TXA to patients, as well as extensive
literature to support the use of TXA as a means to reduce overall perioperative blood loss, the
dosing strategy for the proposed study required determination of an appropriate evidence based
schedule and amount of drug to be administered. George, Sarraf, & Nwaboku (2015) examined
the effect of TXA dose timing on the perioperative total blood loss as well the rate of allogenic
blood transfusion and incidence of thromboembolic complications. Secondarily, the cost of
utilizing the drug was also considered. While this study also focused on primary THA and TKA,
the underlying safety information as well as their findings related to the timing of the
administration of TXA are what was most relevant to the proposed study at Central Maine
Medical Center. Patients in the George, Sarraf, & Nwaboku (2015) study “who received TXA
showed a reduction in immediate postoperative red cell volume loss and total blood loss”
(George, et al., 2015, p. 129). Because of this finding, the primary conclusion of this study was
that “a single perioperative bolus of intravenous TXA may significantly reduce operative blood
loss” (George et al., 2015, p. 129) in a cost-conscious manner. Additionally, George et al.
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(2015) cited the successful use of TXA in the CRASH-2 study on trauma patients to reduce
bleeding and also went on to discuss the large body of scientific publications that “have
confirmed the efficacy of TXA in significantly reducing operative blood loss and reducing the
need for postoperative blood replacement” (George et al., 2015, p. 129).
Similar to George et al. (2015), Sarzaeem et al. (2014) also examined a variety of dosing
schedules and manners of administration of TXA in an effort to reduce perioperative blood loss.
Sarzaeem et al. (2014) conducted a level I evidence study including patients 18 years of age and
older undergoing unilateral TKA due to degenerative arthritis of the knee. Unlike other studies,
patients in this study were not excluded due to prior cardiovascular issues, cerebrovascular
conditions or a history of thromboembolic disorders. Patients in this study were allocated to
groups using a random number list system. Groups were labeled 1-4. Group 1 received
1,500mg of TXA via intravenous injection just prior to incision. Group 2 had the joint
undergoing replacement irrigated with three grams of TXA dissolved into 100mL of normal
saline. Group 3 had 1,500mg of TXA injected into the drain port after surgical closure had been
achieved. Group 4 was the control group and had no TXA of any kind administered. Sarzaeem
et al. (2014) found that the administration of TXA by any method does indeed reduce bleeding as
evidenced by a reduction in the overall level of hemoglobin decrease. The intravenous injection
of TXA appeared to be considerably more efficacious than the irrigation of the joint or wound
drainage port, and that all groups did realize a reduction in bleeding when compared to the
control group (Sarzaeem et al., 2014).
Gomez-Barrena, Ortega-Andreu, Padilla-Eguiluz, Perez-Chrzanowska & FigueredoZalve (2014) examined the difference between topical intra-articular TXA and intravenous TXA
in reducing blood loss during total knee arthroplasty. Results showed the two routes of
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administration to be equally efficacious in regard to the amount of total blood loss and blood
drainage postoperatively. TXA levels were measured in the peripheral blood postoperatively.
When peripheral blood levels of TXA were taken during the postoperative period, the intraarticular group exhibited a TXA level significantly lower than what was observed in the
intravenous TXA group. Administration of topical TXA gave the same results as intravenous
TXA administration in terms of decreasing blood loss and drained blood. However topical
administration of TXA significantly reduces the risk of thromboembolic occurrence by
decreasing systemic circulation of TXA (Gomez-Barrena et al., 2014).
According to Meyeux et al. (2016), when TXA is used to reduce blood transfusion rates,
large institutional cost savings can be realized and potentially passed along to patients. The cost
of one unit of packed red blood cells to the patient is $343 compared to $45-55 for one gram of
TXA. Additionally, blood products may be limited in their availability making administration of
TXA even more desirable. Routine TXA administration, unless contraindicated, has the
potential to drastically improve resource allocation. Administration of TXA decreases the cost to
the patient and also serves to reduce the morbidity and mortality that is a potential result from
blood product administration (Meyeux et al, 2016).
Contraindications to receiving TXA have been put into two categories: absolute
contraindications and relative contraindications (Meyeux et al., 2016). Color blindness,
hypersensitivity to TXA, active intravascular clotting and subarachnoid hemorrhage are
considered absolute contraindications. Evaluation for TXA toxicity is preformed through an eye
exam. The ophthalmic exam is only useful to detect TXA toxicity in patients who have
functioning color vision. In patients who are color blind, providers are not able to distinguish if
TXA toxicity exists and must therefore not be administered TXA (Meyeux et al., 2016). History
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of a vascular occlusive event, administration of a procoagulant therapy, or hormonal
contraceptive use is considered to be relative contraindications for the use of TXA (Meyeux et
al., 2016).
Blood loss in hip fractures starts at the time of injury and continues throughout the
perioperative period. Foss (2006) concluded that total intraoperative blood loss from a hip
fracture is up to six times the amount observed. Hidden blood loss of 547-1,473 mLs contributes
to patient complications postoperatively. Large blood loss during surgery in a vulnerable elderly
population drastically increases medical complications and increased length of hospital stay
(Foss, 2006).
Shokoohi et al. (2012) examined the effects of hip fracture surgery and blood transfusions
on the elderly population. Shokoohi et al. (2012) concluded that blood transfusions did not
confer an increase in mortality but was associated with an increase in postoperative infections
following hip fracture surgery. Mortality was measured at postoperative day 28 and 180. No
difference in transfused versus non-transfused patients was reported. Bleeding is associated with
any type of fracture however in this specific postoperative population, even small amounts of
blood loss put these patients at risk for hypovolemia and anemia. Transfused patients also have
an increase in length of hospital stay when compared to those patients who did not receive
transfusions (Shokoohi et al, 2012). Shokoohi et al. (2012) serves as support for utilizing TXA
as a means of decreasing transfusion rates in the frail elderly population experiencing hip
fractures as an effort to reduce infection rates and decrease length of hospital stay.
Zufferey et al. (2010) studied the use of TXA in hip fracture surgery as a means to reduce
blood loss. One hundred and ten patients participated in the study. Patients received one dose of
TXA prior to incision and a second dose three hours later. The rate of allogenic blood
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transfusion was 42% in the TXA group as compared to 60% in the control group (Zufferey et al.,
2010). A slightly increased incidence of adverse vascular events reported in this study however,
this increase was not statistically significant (Zufferey et al., 2010).
Discussion: Study at Central Maine Medical Center
The number of hip fracture occurrences in the United States is increasing every year, with
the majority of hip fractures happening in a vulnerable elderly patient population. Hip fracture in
this population is associated with a mortality rate of 7-14% while still in the hospital and reaches
14-36% within a year of surgery (Mundi, Pindiprolu, Simunovic, & Bhandari, 2014). An
increased risk of death is associated with a hip fracture and persists for up to six years post injury
(Yonezawa, Yamazaki, Atsumi, & Obara, 2009). Factors contributing to the risk of death within
six years of fracture are: preoperative health status, pre-fracture mobility, age, sex and
comorbidities (Yonezawa et al, 2009). Common comorbidities in this population are dementia,
congestive heart failure, coronary heart disease, previous myocardial infarction, renal failure,
chronic lung disease, and diabetes (Neuman, Rosenbaum, Ludwig, Zubizarreta, & Silber, 2014).
Mortality after hip fracture is linked to a decrease in postoperative mobility that is associated
with a simultaneous decline in overall health status and quality of life (Mundi et al, 2014). Up to
half of all hip fracture patients do not regain their pre-fracture functionality. Additionally, 20%
of hip fracture patients require some form of long-term care due to the inability to preform
activities of daily living and decreased mobility (Tajeu et al., 2013).
For the nine-month period ending on September 30th, 2016, CMMC is experiencing a 19%
transfusion rate for patients undergoing surgical repair of hip fractures in their facility. This
compares to a 1.5% transfusion rate for primary elective hip replacement surgeries where TXA is
being administered prophylactically during the perioperative period. As discussed above in the
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literature review presented, administration of antifibrinolytic therapy during the perioperative
period has been offered as a means to decrease intraoperative bleeding. The reduction in
intraoperative bleeding is assumed to confer a benefit to the patient by reducing the need for
infusion of and sequale associated with allogenic blood and blood product transfusions. The
primary objective of the CMMC study is to determin if the use of TXA reduces perioperative
blood loss and therefore reduces the need for allogenic blood transfusion in patients undergoing
surgery to repair hip fracture. Secondary objectives of this study will examine calculated blood
loss between the TXA and placebo groups, determination if the reduction in allogenic blood
transfusion imparts a parallel reduction in the incidence of complications such as infection,
length of hospital stay, and death. Additionally, we seek to determine if use of TXA in this
patient population imparts an increased risk of adverse vascular events and/or death. Should data
indicate any such increased risk, the study will be terminated prior to scheduled completion and
all current study participants will be notified.
To take part in this prospective, randomized, double-blinded, off label trial study at CMMC,
patients are required to meet certain inclusion criteria. Patients must be greater than 65 years of
age. Patients must present with an acute, traumatic hip fracture sustained after a fall from
standing. Patients who acquired their hip fractures after high impact collisions are excluded
from participation. Patients must freely provide their informed consent. Additionally, patients
meeting inclusion criteria for this study must be without history of treatment with
anticoagulation agents, vascular events such as stroke, myocardial infarction, pulmonary
embolism, deep vein thrombosis, or a clotting disorder. Patients presenting with an unknown
medical history, or if a full medical history cannot be obtained, may not be included in the study.
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Patients may be enrolled into the study by one of the study’s Clinical Research Coordinators.
The Principal Investigator, Co-Principal Investigator, Sub-Investigators, or Clinical Research
Coordinators are able to obtain informed consent from prospective patients or their legal
representative. When patients enter the facility with a hip fracture via the Emergency
Department, the registered nurse (RN) House Supervisor will alert the Clinical Coordinator to
their arrival. This will trigger the Clinical Coordinator to review the patient’s history and
physical, demographics, and nature of their injury. Should the patient meet the inclusion criteria,
outlined in the above paragraph, the Clinical Research Coordinator may approach the patient to
consent them for enrollment into the study. Once informed consent has been obtained, a Clinical
Research Coordinator will then personally deliver the consent to the pharmacy where the consent
will be secured in a locked filing cabinet. Sarah Green, PharmD will be unblinded in this study.
She will produce randomized kits in the CMMC Inpatient Pharmacy numbered from one to 125.
Randomized TXA and placebo kits will be created in batches of 20. Half of the kits will contain
TXA and half will contain placebo. As patients are added to the study, the Inpatient Pharmacy
will dispense the kits based on the patient’s number of entry into the study. When a patient is
enrolled into the study by a Clinical Research Coordinator, they will be sequentially added to the
study list and tracked by FIN number within the Inpatient Pharmacy by Sarah Green. No
personal identifier will be used in the randomization. No one participating in the study, patient
or provider, will have access to identifying information enabling him or her to determine which
patients are receiving active drug vs. placebo. Thus meeting the definition of calling a study
double blinded. Participants in the placebo group will be administered 100 mL of normal saline
15 minutes prior to skin incision. Participants in the intervention group will be administered
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1,000 mg tranexamic acid reconstituted into 100 mL of normal saline 15 minutes prior to skin
incision.
A wide variety of dosages and timing regimes for a single perioperative dose of TXA
were examined throughout the literature search and review. The findings presented by George et
al. (2015) were utilized to determine the most efficacious timing for the dose of TXA to be
administered to the traumatic hip population being examined in the CMMC study. George et al.
(2015) determined a single 1,000 mg dose of TXA would confer the previously reported benefit
of reduced bleeding. This is a simplified and conservative dosing schedule that has been shown
to reduce bleeding and was therefore chosen due to both its simplicity as well as its demonstrated
efficacy.
In the postoperative period all patients will have vital signs and hemoglobin and hematocrit
levels monitored per institutional standards of care. Vital signs will be checked every four hours
and laboratory values will be checked daily, or more frequently at individual provider discretion.
Patients meeting institutional requirements for a blood transfusion during either the
intraoperative or postoperative period will be considered for the primary outcome. As stated in
our hypothesis in Appendix A: IRB Application, we expect the pre-incision administration of
TXA will reduce the rate of intraoperative and postoperative allogenic blood transfusion.
The patient’s independent medical team on the institution’s Hospitalist service will determine
the need for and if criteria are met for blood transfusion. CMMC protocol requires patients meet
certain requirements prior to receiving allogenic red blood cell transfusion. In the setting of
active bleeding institutional requirements for red blood cell transfusion include: acute blood loss
of >25% of blood volume unresponsive to fluid resuscitation, acute blood loss with a
hemoglobin of <9g/dL with moderate to severe cardiovascular disease, or a decrease in
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hemoglobin level of 2g/dL within 24 hours with a hemoglobin of less than 8g/dL or hematocrit
less than 24g/dL with signs or symptoms of anemia. Signs or symptoms of anemia are defined
as fatigue, pallor, shortness of breath, lightheadedness, heart rate >100 beats per minute, and lab
values revealing hemoglobin and hematocrit levels less than 9g/dL and 24g/dL respectively. As
previously stated, an independent medical team will follow patients who require transfusion of
blood products. Patients will receive post transfusion evaluation of hemoglobin and hematocrit
levels at time intervals determined to be medically necessary by the hospitalist or surgeon
responsible for their care. Typically, patients will receive daily checks of hemoglobin and
hematocrit level until they are able to maintain a stable hemoglobin level >7g/dL and hematocrit
level >21g/dL in the absence of the signs or symptoms of anemia previously described.
Patients participating in this study will be allowed to ambulate in the same manner as all
other orthopedic surgical patients. Postoperative weight bearing will be allowed as tolerated.
DVT prophylaxis will follow standard hospital procedure. Patients will receive 5,000 units of
subcutaneous heparin on admission and every eight hours thereafter until 12 hours prior to
surgery. Six hours post surgical intervention, patients will resume heparin therapy.
Additionally, when patients are not participating in physical rehabilitation activities, sequential
calf compression devices shall also be utilized to further reduce the risk of developing DVT.
Determination of blood loss will be calculated in the manner described below.
•

Estimated blood volume (EBV) preop: weight in kg * average blood volume mL/kg
o Adult men: 75mL/kg
o Adult women: 65 mL/kg

•

Multiplying the estimated blood volume by the hematocrit gives the red cell volume.
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Performing the calculation preoperatively and postoperatively then computing the
difference calculates pre-operative vs. post-operative changes in red cell volume.
o Pre-op RBC volume = EBV * pre-op Hct
o Post-op RBC volume = EBV * post-op Hct
o Operative RBC volume loss = Pre-op RBC volume – Post-op RBC volume

Infection at the site will be characterized and reported per institution protocol. Adverse
vascular events that may be considered include myocardial infarction as diagnosed by a
cardiologist based on ECG changes, elevated biological markers (creatine kinase, troponin), or
echocardiogram changes and symptomatic DVT verified by ultrasound venography, pulmonary
embolism confirmed by CT scan of the chest, pulmonary angiography, echo-cardiologic
visualization or visualization of thrombus at autopsy.
This study has been approved by the IRB at Central Maine Medical Center to run for one
years time with a goal N=125. Should the number of patients enrolled for outcome examination
fail to be achieved in the approved timeframe, application for extensions will be considered on a
yearly basis by the IRB. To date, there have been 12 patients enrolled into the study. Data will
be collected and examined on a quarterly basis. The first gathering of raw data is to occur at the
end of March 2017. Given the considerably lower than expected number of patients willing and
able to be enrolled into the ongoing study, the Central Maine Medical Center research team is
currently reexamining the schedule for data collection and review. Currently, deliberation
continues regarding what would represent the most efficient and productive time schedule to
convene and assess data collected to date.
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Conclusion
A multitude of recent and high quality studies that have been conducted validate the efficacy
and safety of TXA administration. A wide range of patient populations presenting with varied
surgical needs were examined within each of these research studies. Results have shown that
without question, use of TXA during a variety of scheduled orthopedic procedures has been
revealed as an effective means to decrease blood loss during the perioperative surgical period
(Zufferey et al. 2006). The reduction of intraoperative bleeding is assumed to confer a benefit to
the patient by reducing the need for infusion of, and sequale associated with, allogenic blood and
blood product transfusions (Das et al. 2013). However, a significant gap in current literature
exists. Very few recent high-quality studies examine administration of TXA to hip fracture
patients. Of those, Zufferey et al. (2010) is perhaps the most germane to the study currently
being conducted at Central Maine Medical Center. Zufferey et al. (2010) examined the rates of
allogenic blood transfusion after two doses of TXA, as discussed above in the literature review
section of this paper. This study utilized a small number of patients, N=100, and showed a nonstatistically significant increase in the number of adverse vascular events. The limitations of the
Zufferey et al. (2010) study were its small size, limited duration, and inability to determine with
any statistical importance if an increase in adverse vascular occlusive events can be seen when
administering TXA to patients undergoing surgery for correction of a traumatic hip fracture. The
study underway at CMMC plans to address these two shortcomings of the previously conducted
study by Zufferey et al. (2010).
The ongoing study being conducted out of Central Maine Medical Center aims to provide
high-quality evidence to support the use of TXA in the traumatic hip fracture population. This
will be done by increasing the number of patients examined from the N=100 cases considered by
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Zufferey et al. (2010) to N=125. The increase in sample size will increase the power of any
hypothesis testing done at the completion of the study. The duration of the study is currently
approved for one year however, may be easily extended with submission of a renewal
application to the CMMC IRB. Given the expedited approval received after submission of the
initial application, it is expected renewal and extension will not be an issue. The CMMC study
utilizes a single dose of TXA and is expected to improve overall patient outcome through the
reduction of blood loss while concomitantly maintaining a low level of vascular sequale that may
be attributed to the use of an antifibrinolytic therapy in the setting of trauma.
Numerous studies, as discussed in detail above, support the use of TXA in elective joint
replacement surgery to decrease perioperative blood loss. Some of these studies also
demonstrate that TXA administration decreases blood transfusion rates, length of hospital stay,
and cost to the patient. Patients undergoing elective orthopedic surgery have been medically
optimized to achieve the most successful outcomes. Patients who have sustained a traumatic hip
fracture may not be optimized and are therefore more likely to be considered fragile given their
age, trauma status, preoperative baseline health, and presence of perioperative blood loss. When
considering these factors, decreasing blood loss during the perioperative period and reducing the
need for allogenic transfusion is likely to realize improved postoperative outcomes in this patient
population.
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Appendix A
IRB Application
Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures
List of Abbreviations:
TXA: Tranexamic Acid
CMMC: Central Maine Medical Center
DVT: Deep Vein Thrombosis
LOS: Length of Stay
ENT: Ear Nose and Throat
Principal Investigator, Research Team, and Study Site:
Principal investigator: Morgan Guerrette
Co-Principal Investigator: Katherine Balzano-Cowan
Clinical Research Coordinators: Tina Moring, Sarah Green, James Osgood, Elizabeth
Turcotte, Jay Bachelder, Robyn Begin, Carie Whitmore, Maija Comeau, and Diane Jeselskis
Study site: Central Maine Medical Center
Study Information:
Study Title: Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures
Study Population: Any patient greater than 65 years of age presenting with traumatic hip
fracture
Study Design
Sample Size: n=125
Study Duration: 1 year
Study Agent: Tranexamic acid
Primary Objective: Determination if the use of TXA reduces perioperative blood loss and
therefore reduces the need for allogenic blood transfusion in patients undergoing surgery to
repair hip fracture.
Secondary Objectives:
Secondary objectives of this study will examine calculated blood loss between the TXA and
placebo groups, determination if the reduction in allogenic blood transfusion imparts a
concomitant reduction in the incidence of complications such as infection (defined below), LOS,
and death. Additionally, we seek to determine if use of TXA in this patient population imparts
an increased risk of adverse vascular events (defined below) and death.
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Intervention Description: Study participants will be assigned to either the placebo group or the
intervention group. Participants in the placebo group will be administered 100mL of normal
saline 15 minutes prior to skin incision. Participants in the intervention group will be
administered 1,000mg tranexamic acid reconstituted into 100mL of normal saline 15 minutes
prior to skin incision.
All patients will have vital signs and hemoglobin and hematocrit levels monitored per
institutional standards of care. Patients meeting institutional requirements for a blood
transfusion (see below) during either the intraoperative or postoperative period will be
considered for the primary outcome. We expect the pre-incision administration of TXA will
reduce the rate of intraoperative and postoperative allogenic blood transfusion.
The patient’s independent medical team will determine the need for and if criteria are met for
blood transfusion. CMMC protocol requires patients meet the following requirements prior to
receiving allogenic red blood cell transfusion:
In the setting of active bleeding a patient must have:
1) Acute blood loss of >25% of blood volume unresponsive to fluid resuscitation
Or
2) Acute blood loss with a hemoglobin of <9 with moderate to severe cardiovascular disease
Or
3) A decrease in hemoglobin level of 2gm/dL within 24h with a hemoglobin of less than
8/hematocrit less than 24 with signs or symptoms of anemia
An independent medical team will follow patients receiving transfusion of blood products.
Patients will receive post transfusion evaluation of hemoglobin and hematocrit levels at time
intervals determined to be medically necessary by the hospitalist or surgeon responsible for their
care. Typically, patients will receive daily checks of hemoglobin and hematocrit level until they
are able to maintain a stable hemoglobin level >7 and hematocrit level >21 in the absence of
signs or symptoms of anemia.
Patients participating in this study will be allowed to ambulate in the same manner as all other
orthopedic surgical patients. Postoperative weight bearing will be allowed as tolerated. DVT
prophylaxis will follow standard hospital procedure. Patients will receive 5,000 units of
subcutaneous heparin on admission and every 8 hours thereafter until 12 hours prior to surgery.
6 hours post surgical intervention patients will resume heparin therapy. Additionally, when
patients are not participating in physical rehabilitation activities sequential calf compression
devices shall also be utilized to further reduce the risk of developing DVT.
Blood loss will be calculated using the following:
• Estimated blood volume (EBV) preop: weight in kg * average blood volume mL/kg
o Adult men: 75mL/kg
o Adult women: 65 mL/kg
• Multiplying the estimated blood volume by Hct gives the red cell volume
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Performing the calculation preoperatively and postoperatively then computing the
difference calculates pre-op vs. post-op changes in red cell volume.
o Pre-op RBC volume = EBV * pre-op Hct
o Post-op RBC volume = EBV * post-op Hct
o Operative RBC volume loss = Pre-op RBC volume – Post-op RBC volume

Infection at the site will be characterized per institution protocol.
Adverse vascular events may be considered:
• Myocardial infarction as diagnosed by a cardiologist based on ECG changes, elevated
biological markers (CK, troponin), or echocardiogram changes.
• Symptomatic DVT verified by ultrasound venography, pulmonary embolism confirmed
by CT scan of the chest, pulmonary angiography, echo-cardiologic visualization or
visualization of thrombus at autopsy.
Background and Significance:
As of Q3 2016, CMMC is experiencing a 19% transfusion rate for patients undergoing surgical
repair of hip fractures in our facility. This compares to a 1.5% transfusion rate for primary
elective hip replacement surgeries where TXA is being administered prophylactically during the
perioperative period.
Administration of antifibrinolytic therapy during the perioperative period has been presented as a
means to decrease intraoperative bleeding. The reduction in intraoperative bleeding is assumed
to confer a benefit to the patient by reducing the need for infusion of and sequale associated with
allogenic blood and blood product transfusions (5,16). One antifibrinolytic in particular,
tranexamic acid (TXA), has been well studied for use in scheduled elective orthopedic surgery
with emphasis on total hip arthroplasty and total knee arthroplasty (1, 6, 8, 11). TXA is a lysine
amino acid derivative that prevents break down of the fibrin clot. TXA competitively binds to
plasminogen. This competitive binding action obstructs naturally occurring lysine from binding
with plasminogen thus preventing the formation of the enzyme plasmin. Inhibition of the
conversion of plasminogen to plasmin preserves the formed fibrin clot thereby decreasing blood
loss at the site of bleeding or injury via clot stabilization (2, 8, 9,).
CRASH-2 (27) is one of the largest studies to date conducted for the purpose of examining the
effects of TXA administration. CRASH-2 assessed the use of TXA in trauma patients with the
goal of reducing death rates due to uncontrolled bleeding. Results from CRASH-2 showed a
significant decrease in bleeding following trauma and ultimately determined that the
administration of TXA to trauma patients yielded a decrease in the observed death rate (27).
Due to the promising results observed in the CRASH-2 study, The World Health Organization
(WHO) was prompted to add TXA to its list of essential medications for trauma and those at
significant risk of ongoing hemorrhage (2, 10).
Currently, the FDA approved on-label indications of TXA are use in the short-term treatment of
hemophilia patients undergoing dental extractions and in the management of patients
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experiencing menorrhagia (10). Despite the current limited scope of FDA approval for TXA,
antifibrinolytic therapy use during elective surgery in otherwise clotting-uncompromised patients
is not a new concept. TXA has been administered in cardiopulmonary bypass, ENT, orthopedic,
spinal fusions, and hysterectomies as an aid to decrease blood loss. Numerous studies have
examined the efficacy, and safety, of TXA use for the reduction of intraoperative blood loss in
orthopedic surgeries specifically, total knee and total hip arthroplasty (21). In reports examining
lower total joint replacement surgeries, TXA reduced intraoperative blood loss, rate of allogenic
blood transfusions, and total length of hospital stay (18,19,20,22). All of these individual results
appear to work synergistically and ultimately resulted in a reduction in the overall cost of the
procedure and decreased costs relayed to the patients (8, 11,16). Limited research exists
examining the efficacy of TXA administration in the perioperative period for the traumatic hip
fracture population. Based on the entire body of prior research conducted to date, it is reasonable
to hypothesize that administration of TXA in these traumatic instances would also yield a
decreased blood loss and therefore could possibly contribute to lower rates of allogenic blood
transfusion in the traumatic hip fracture population.
Each year over 300,000 hip fractures occur in the United States. This number is projected to
increase to over 500,000 by the year 2040 (23, 25). In the >65-year-old population, one-year
mortality rate associated with hip fracture is between 12% to 36% in the 65 and older population
and the 5-year mortality rate reaches upwards of 60% (24, 25). Factors affecting mortality
include pre-existing comorbid conditions, preoperative health status, pre-fracture mobility, age,
and sex (9). With blood loss beginning at the moment of injury and continuing through out the
postoperative recovery period, typical patients may experience an average perioperative blood
loss in upwards of 1500 mLs (28,12). Significant blood loss in an already vulnerable elderly
population has the potential to dramatically increase the need for allogenic blood transfusions.
Allogenic blood transfusions have been linked to an increase in postoperative infection rates and
prolonged hospital stays (3,11). Patients that receive allogenic blood transfusions are twice as
likely to develop an infection when compared to non-transfused patient cohorts (3).
Cardiac disease and renal disease are common comorbid conditions exhibited by a majority of
the elderly hip fracture patient population (9). Patients with significant cardiac disease have an
increased incidence of poor outcomes in the presence of large volume blood loss. Patients with
pre-existing renal compromise are at risk for pulmonary complications associated with volume
loading during receipt of allogenic blood transfusion. Reduction of allogenic blood transfusions
in both the renal and cardiac compromised hip fracture population has the potential to
significantly decrease the risk of known adverse events frequently seen in patients with these
pre-existing comorbid conditions.
Lee et al (29) examined the efficacy of TXA administration in patients receiving hip
hemiarthroplasty surgery following a hip fracture. Transfusion rates within the TXA group were
reported at 6% and for those in the placebo group at 19%. Zuffrey et al (7) explored the use of
antifibrinolytics in orthopedic surgery to reduce allogenic blood transfusions. Three
antifibrinolytic were used in this study: aprotinin, amicar and TXA. For the purpose of this study
only results pertinent to TXA will be discussed. Primary surgeries investigated included total
knee arthroplasty and total hip arthropalasty. Allogenic blood transfusion rates and the total
perioperative blood loss were significantly (P<0.01) decreased when TXA was administered.
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Zuffrey et al (7) also examined complications in the setting of antifibrinolytic administration.
The rate of venous thromboembolism in the TXA group (20.9%) was no different when
compared to the control group (20.8%).
In a second study by Zufferey et al (15) the use of TXA in hip fracture surgery was studied. One
hundred and ten patients participated in the study. Patients received one dose of TXA prior to
incision and a second dose 3 hours later. The rate of allogenic blood transfusion was 42% in the
TXA group as compared to 60% in the control group. A slightly increased incidence of adverse
vascular events reported in this study was not statistically significant (15).
Poren et al (13) investigated the safety of TXA use in 872,416 patients undergoing total hip
arthroplasty and total knee arthroplasty. The primary outcome of this study was TXA use to
decrease allogenic blood transfusions while not increasing the risk for thromboembolic
complications. Patients that received TXA exhibited an allogenic transfusion rate of 7.7% while
the control group had at 20.1% transfusion rate. Thromboembolic complications occurred at a
rate 0.6% in the TXA group as compared to 0.8% in the control group. Poren et al demonstrated
the ability of TXA to decrease the requirement of allogenic blood transfusions while not
significantly increasing adverse vascular outcomes.
Das et al (14) focused their study solely on the use of TXA in patients undergoing hip fracture
surgery. Patients were either an ASA (American Society of Anesthesiologist) physical
classification status I or II between the ages of 18-80. Of the 90 participants in this study, 45
were randomized into the test group and received TXA while 45 were randomized into the
control group and did not receive TXA. Primary outcomes for this study included examination
of the volume of blood in the patients surgical site drain postoperatively, percentage of
hemoglobin fall on postoperative day 0 and day 2, and allogenic blood transfusion rates. The
blood volume output into the surgical site drains for the TXA group was 39.33+/-10.09ml
compared to 91.11+/-17.61 in the control group. Hemoglobin drop in the TXA on day 0 was
2.99+/-3.45 compared to the control group of 7.70+/-6.05. On postoperative day 2, TXA
hemoglobin drop was 0.35+/-0.74 and the control group was 2.72+/-2.7. Eighteen of the 45
patients in the control group received an allogenic blood transfusion while only 7 out of 45
patients in the TXA group required transfusion.
A 2011 Cochran Review (30) examined the effect of using TXA vs. placebo on the rate of
allogenic blood transfusion and adverse vascular events. A total of 4,842 patients were
randomized into either the TXA group or the control group receiving a placebo. The population
receiving TXA realized a reduction in the rate of allogenic blood product transfusion of 39%.
Furthermore, the risk of adverse vascular events such as myocardial infarction, stroke, deep vein
thrombosis, pulmonary embolism, or development of renal disease or dysfunction did not
increase when TXA was administered. Also, the use of TXA was not associated with an increase
in risk for mortality (30).
Literature review has shown that limited evidence exists looking at the efficacy of TXA use for
decreasing allogenic blood transfusion in hip fracture patients. This study aims to provide high
quality evidence to support the use of TXA in the traumatic hip fracture population. Use of a
single dose of TXA is expected to improve overall patient outcome through the reduction of
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blood loss while concomitantly maintaining a low level of vascular sequale that may be
attributed to the use of an antifibrinolytic therapy in the setting of trauma.
Numerous studies support the use of TXA in elective joint replacement surgery to decrease
perioperative blood loss, decrease blood transfusion rates, decrease length of hospital stay, and
decrease cost to the patient. Patients undergoing elective orthopedic surgery have been medically
optimized to achieve the most successful outcomes. Patients who have sustained a traumatic hip
fracture may not be optimized and are therefore more likely to be considered fragile given their
age, trauma status, preoperative baseline health, and presence of perioperative blood loss. When
considering these factors, decreasing blood loss during the perioperative period and reducing the
need for allogenic transfusion is likely to realize improved postoperative outcomes in this patient
population.
Objectives:
Primary Objective: Determine if the use of TXA reduces perioperative blood loss and
therefore reduces the need for allogenic blood transfusion in patients undergoing surgery to
repair hip fracture.
Secondary Objectives: Determine if the reduction in allogenic blood transfusion imparts a
concomitant reduction in the incidence of complications such as infection, LOS, and death.
Determine if use of TXA in this patient population imparts an increased risk of adverse vascular
events and death.
Study design/methodology:
This is a prospective, randomized, double-blinded, off label trial. Any patient at or over the age
of 65 presenting to CMMC for the ORIF repair of a traumatic hip fracture may be considered for
inclusion in this study.
Patients may be enrolled into the study by one of the study’s Clinical Research Coordinators.
The Clinical Research Coordinators able to obtain informed consent are the M2 Clinical
Coordinators Jay Bachelder, Robyn Begin, Carie Whitmore, or Maija Comeau. When patients
enter the facility with a hip fracture via the Emergency Department, the RN House Supervisor
will alert the M2 Clinical Coordinator to their arrival. This will trigger the Clinical Coordinator
to review the patient’s history and physical, demographics, and nature of their injury. Should the
patient meet the inclusion criteria outlined below, the Clinical Research Coordinator may
approach the patient to consent them for enrollment into the study. Informed Consent will be
obtained by reading the Informed Consent literature to the patient and answering any questions
that may arise. The Clinical Research Coordinator will then personally deliever the consent to
the pharmacy where the consent will be secured in a locked filing cabinet.
Study Population:
Inclusion/Exclusion Criteria:
Inclusion Criteria: Any patient over the age of 50 presenting to Central Maine Medical
Center with hip fracture that consents to participate in the study may be included in the study.
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Exclusion Criteria: Patients who are anticoagulated or have a history of vascular events
such as stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis or a clotting
disorder. Patients with unknown medical histories or if a full medical history can not be obtained
they will be excluded from the study.
Study Drug/Interventions:
Study participants will be randomly assigned to either the placebo group or the intervention
group. Participants in the placebo group will be administered 100mL of normal saline 15
minutes prior to skin incision. Participants in the intervention group will be administered
1,000mg tranexamic acid reconstituted into 100mL of normal saline 15 minutes prior to skin
incision.
Sarah Green, PharmD will be unblinded in this study. She will produce randomized kits in the
CMMC Inpatient Pharmacy numbered from 1 to 125. Randomized TXA and placebo kits will be
created in batches of 20. ½ of the kits will contain TXA and ½ will contain placebo. As patients
are added to the study, the Inpatient Pharmacy will dispense the kits based on the patient’s
number of entry into the study. When a patient is enrolled into the study by one of the Clinical
Research Coordinators, they will be sequentially added to the study list and tracked by FIN
number within the Inpatient Pharmacy by Sarah Green. No personal identifier will be used in the
randomization.
Study Schedule:
The study will take place starting 01/11/2017 to 01/11/2018
Adverse Event Reporting:
Adverse events are entered into the MIDAS system at CMMC. Either the RN or provider
responsible for direct patient care may make entries into the MIDAS system. All adverse events
related to orthopedic patients involved in this study will be reported to Elizabeth Tourcotte.
Statistical Analysis Plan:
N=125
Defer to statistician.
Informed Consent Process:
Privacy and confidentiality
Privacy and confidentiality will be maintained pursuant to hospital policy and standards.
Patients or their healthcare decision makers will be verbally consented by their surgeon prior to
enrollment in the study. Signed consent forms will be obtained as verification. Additionally, an
informational handout detailing the study objectives as well as potential risks and benefits to
participation will be provided to patients at the time of consent.
Risk/Benefit:
Risk to participants:
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Adverse vascular event including, but not limited to, myocardial infarction, symptomatic DVT,
pulmonary embolism are possible. Zuffery et al (15) reported the probability of vascular events
at 6 weeks post recipt of TXA was 16% vs. 6% in their placebo group while a larger study
conducted by Das et al (14) reported no thromboembolic episodes. It was suggested that TXA
will not affect the risk of DVT due to its mechanism of action whereby TXA inhibits fibrinolysis
in the wound but not in circulation.
Medications that have been shown to have an interaction with IV TXA:
• Anti-inhibitor Coagulant Complex (Examples: Autoplex T, Feiba NF, Feiba VH
Immuno): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor
Coagulant Complex. Combination should be avoided
• Contraceptives-Estrogens and Progestin (Examples: Yaz, Desogen, brevicon) May
enhance the thrombogenic effect of Tranexamic Acid. R
• Fibrinogen Concentrate (Examples: haemocomplettan, fibrinogene T1 and Clottagen):
Antifibrinolytic Agents may enhance the adverse/toxic effect of antifibrinolytic agenst.
Specifically, the risk for thrombosis may be increased.
• Tretinoin (Examples: Avita, Renova, Retin-a): May enhance the thrombogenic effect of
Antifibrinolytic Agents.
Benefits to participants:
Reduction in blood loss after experiencing a traumatic hip fracture. The additional benefits
stemming from a reduction in blood loss are the reduction in the need to receive blood products.
Allogenic blood product transfusion carries with it some level of risk which is outlined in other
areas of this research proposal in more detail.
Study Timeline:
1 year
Data Safety Monitoring:
CMMC currently utilizes the MIDAS system for reporting and follow-up on any adverse patient
events. Elizabeth Turcotte will be notified directly through the MIDAS reporting system of any
adverse event occurrence as described above. Elizabeth Turcotte will present any adverse events
reported during monthly data reporting meetings with the group at large. Informed consent is
only for use in enrolling patients into the TXA study and not used as a consent for surgical
intervention. The TXA study consents will be secured in pharmacy in a filing cabinet that is
locked at all times, it is not to become part of the patients’ chart.
The coordinators will take the consents and bring to the pharmacy to then be secured.
Conflict of Interest:
None
Publication and Presentation Plans:
Morgan and Kate will be using this as capstone project and presenting at UNE Research day.
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Appendix B

Central Maine Healthcare Corporation
INSTITUTIONAL REVIEW BOARD

Central Maine Medical Center
Bridgton Hospital
Rumford Hospital
Deborah Taylor, Ph.D., IRB Chair
Jenae Limoges, MD, IRB Vice-chair
Phone: (207) 795-8246
Fax: (207) 344-0373

Lois N. Downs, IRB
Risk Management
300 Main Street
Lewiston, Maine 04240

APPLICATION (FULL BOARD)
Protocol Title:
Utilizing Tranexamic Acid to Reduce Blood
Transfusion in Hip Fractures

Principal Investigator:
Morgan Guerrette SRNA

Application for Human Subject Research
Applications for human subject research will need to meet all outlined requirements listed for each type of
review in order for a project to be reviewed. If you have any questions regarding how to complete the
forms or need help locating a form, please call our office at 207-795-8246.
Authority of the IRB and IRB Review
The IRB determines if a project meets the federal definition of research: “a systematic investigation
including research development, testing and evaluation, designed to develop or contribute to generalizable
knowledge.” The IRB defines a human subject as: “a living individual about whom an investigator
conducting research obtains: 1) data through intervention or interaction with the individual, or 2)
identifiable private information.” This determination is made with the aid of the OHRP guidance
document: Human Subject Regulations Decision Charts, dated September 24, 2004.
Types of IRB Review
There are three levels of IRB Review (full board, expedited and exempt), determined by the nature of the
project, level of potential risk to human subjects and the subject population.
Exempt and expedited review can be given to studies that constitute no more than
minimal risk to the human subjects, i.e., the risk one experiences in daily living. These
reviews are done in the IRB office on a continual basis.
Full board review is required for studies that involve greater than minimal risk or
vulnerable populations that require special protections by the IRB. These require
review by the convened IRB.
Research Proposals Involving the Use of Protected Health Information (PHI)
How Can Covered Entities Use and Disclose Protected Health Information for Research and
Comply with the Privacy Rule?
Key Points:
•

De-identified health information, as described in the Privacy Rule, is not PHI, and thus is not
protected by the Privacy Rule. (See List of Identifiers )

•

PHI may be used and disclosed for research with an individual's written permission in the form of
an Authorization.
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PHI may be used and disclosed for research without an Authorization in limited circumstances:
Under a waiver of the Authorization requirement, as a limited data set with a data use agreement,
preparatory to research, and for research on decedents' information.
Submission and Review Procedure for Full Board Review

The IRB will provide written notification of the IRB’s determination within ten (10) business days. This
notification will be sent via email. There is requirement for notification of revisions to the IRB for full
board approvals for changes that may impact the risk/classification of the project. The IRB does require
notification of unanticipated events or continuing review of a research that is determined full board.
(continued)
APPLICATION (FULL BOARD)

Title of Protocol:
Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures

Principal Investigator (PI): Morgan Guerrette,
SRNA
(Person personally responsible for the conduct of
the research)
Co-Principal-Investigator
Balzano-Cowan, SRNA

(co-PI):

Katherine

(Person equally responsible for the conduct of the
research)
Sub-Investigator: Tina Moring, Sarah Green,
James Osgood, Elizabeth Turcotte
(Person who is a member of the research team
designated and supervised by the investigator to
perform study-related procedures and/or to make
important study-related decisions)

Dept/Address: CMMC
Anesthesia Department
300 Main Street
Lewiston ME 04240

Phone:
2669

207-795-

Dept/Address: CMMC
Anesthesia Department
300 Main Street
Lewiston ME 04240

Phone:
2669

207-795-

Dept/Address: CMMC
Anesthesia Department
300 Main Street
Lewiston ME 04240

Phone:
2669

207-795-

Funding/Protocol Information
Who wrote the protocol or plan for this study?
Funder/Sponsor (listed below under C)
(please choose only one)
Cooperative Group PI:
Principal Investigator: (listed above)
Other:
Is this protocol being supported by a federal funding
agency or non-funded
e.g. NIH, AHA, etc.?
What funding agency is supporting your protocol:
Is this protocol being sponsored by an Industry
(Pharmaceutical or Device) Sponsor?

Yes

No

If yes, please provide a copy of the entire Grant
(research plan) for review.
Grant Title:
Yes

No

(Please list the company below, even if you are not receiving monetary support.)
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(continued)
APPLICATION (FULL BOARD)
Name of Industry Funder/Sponsor:
Contact Person & Title:
Address:
Address:
Phone:
Fax:

If this protocol is not being funded by either a funding
agency, or an industry sponsor, please indicate where
the funding for the conduct of this protocol is being
obtained (if any):

Non-Funded
Departmental Funding
Cooperative Group

Location of Research
Where will the study take place?
Will the PI be conducting and/or supervising study
related activity at any sites not under the jurisdiction of
this IRB/Privacy Board?

Central Maine Medical Center
Yes

No

If yes, please attach to this application and provide name
and address for each location AND documentation of
approval to conduct the research at these sites.

Note: CMHC IRB approval of your protocol does not include permission to perform any protocol-related
activities at these sites. Additional IRB approval may be required from these sites.

(continued)
APPLICATION (FULL BOARD)
Will this study require hospital admission?

Yes

No

If yes, you must notify the Admissions Department at
755-3892 after IRB approval.
Do you have attending privileges at CMHC (CMMC,
Rumford Hospital, Bridgton Hospital)?

Yes

No

Are you an employee of CMHC (CMMC, Rumford

Yes

No
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Hospital, Bridgton Hospital)?
If no, to both question you must have a CMHC sponsor.

Please provide the name of that person:
Tina Moring

Subject Information
Subjects will be: (check all that apply)

Inpatients

Outpatients

Non-Patients
Will subjects who do not understand English be enrolled?

Yes

Males

Females

No

If yes, describe your resources to communicate with
these subjects: Indemand interpreting services
Potentially Vulnerable Populations:

Children

Prisoners

None

Students

Pregnant Women

Other(describe):

Recruitment
How many subjects does your site anticipate recruiting?

125

Who will be approaching potential subjects for informed
consent?

Dr. David Brown MD
Dr. Jeffrey Bush MD
Dr. Matthew Bush MD
Dr. Paul Cain MD
Dr. Patrick Fallon MD
Dr. Michael Regan MD
Dr. James Timoney Do

(continued)
APPLICATION (FULL BOARD)
How much time will subjects have to make a decision
about study participation?
Potentially Vulnerable Populations:

15 min

How will subjects be identified as potential research
subjects?

When CMO is consulted for ORIF of hip fracture in
the emergency room

How will subjects be recruited for participation?

By chart /database review
Course participants
From the Investigator’s own patients
Living conditions (street, nursing home)
Referrals
Circumstance (i.e.hospital admission, homeless)
Describe any other sources:
Direct Advertising
List here:

At a scheduled visit by the investigator
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Letter (Please attach letter to this application)
Phone
Other (describe): when patient is consented for
surgery
By chart / database review
Who is the custodian of the above indicated chart(s) /
database(s) used for recruitment?

surgeons

Describe how the custodian is going to contact the
subject(s).

Via consent/flagged in the ED prior to surgery

Initial contact to potential subjects must be made by the custodian of the chart(s)/database(s).
Please attach any letters, ads or other information that will be sent to the subjects.
Direct advertising for subject recruitment includes:
Radio
Newspaper
Internet

Television

Letters to patients

Bulletin board / flyer

None

Other

(continued)
APPLICATION (FULL BOARD)
Payment to Subjects
Will subjects be paid for participation?

Yes

No

If yes, indicate total amount, (dollar or equivalent):
Form of Payment:
(Payment includes all types of reimbursement such as
fares, parking fees, etc.)
Explain how payments will be made and if the payments
are prorated please explain why?
Are there any services that will be provided without
charge?

Yes

No

Explain these services if answer is yes:

Type of Research
Are there any services that will be provided without
charge?

Yes

No

If yes, name of radioactive drug(s):
Does study involve the administration of radioactive
drug(s)?

Yes

No
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Yes

No

If yes, name of procedure(s):
Number of procedures:
Does study involve psychological tests?

Yes

No

If yes, tests to be used:
(continued)
APPLICATION (FULL BOARD)
Type of Research
Does the study involved the use of questionnaires?
Yes

No

If yes, provide copies of the questionnaires.
Does study involve the use of discarded human
tissue/fluids?

Yes

No

Does study involve the use of fetal and abortus tissues?

Yes

No

Does study involve surgical procedures?

Yes

No

Does study involve dental procedures?

If yes, procedures to be used:
ORIF of hip fracture
Yes
No
If yes, procedures to be used:

Does study involve videotaping/audiotaping or use of
photographs

Yes

No

Does study involve blood draws?

Yes

No

Separate draw for research purposes, or
Additional draw during diagnostic testing
Amount per draw:
Does the study involve any procedures/tests that are not
included above?

Yes

ml

# of draws:

No

If yes, include a list of these procedures/tests:
Is this study already open nationally?

Yes

No
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If yes, include all updates and Data Safety Monitoring
Board (DSMB) reports.
Past individual Adverse
Event Reports are not necessary.

(continued)
APPLICATION (FULL BOARD)
Does this Project Involve Investigational Drugs/Devises (IND/IDE)

Yes

No

If yes complete this section and submit an Investigational Drug or Device Data Form.

This study involves a
drug or biologic:
Yes

IND#:

Name of Drug or biologic: Sponsor of Drug or
biologic:

No

This study
Phase 1
Phase 2
is:
This study involves a IDE#:
device:
Yes

Phase

Phase 4

Treatment

3
Sponsor of Drug or biologic: Sponsor of Drug or
biologic:

No

This device
is:

Investigational

Humanitarian
exemption

Marketed

Significant
Risk Device

NonSignificant Risk
Device*

*Sponsor must include justification on Non-Significant Risk per 21 CFR 812.66
Please Provide Brief Synopsis of Protocol below:
Summary of Protocol is Attached

The undersigned accepts responsibility for assuring that with regard to this protocol, all applicable FDA
and HHS regulations and Institutional Policies relative to the protection of the rights and welfare of
human research participants are adhered to.
Morgan Guerrette
2016
Signature

October 14,
Date

Morgan Guerrette
Print Name

Principle Investigator
Title

The undersigned acknowledges a review and examination of this research proposal has been completed
and assures that this study is appropriate to be conducted at CMHC and that all funding, staffing and
budgetary concerns will be approved before enrollment begins. This authorization is required before the
Principal Investigator can submit this project to the IRB for review.
_________________________________________
Signature of Chair/Vice-Chair

______________________________
Date

(continued)
APPLICATION (FULL BOARD)
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*HIPAA waiver criteria (check all that apply)
If “PHI” being used? ….
(see list of identifiers attached)

Yes (If “Yes” please include HIPAA authorization
language in the informed consent)

Is HIPAA Authorization language required?

No(Can only be “No” if *Informed Consent waiver
and *HIPAA waiver criteria are met)

The use or disclosure of protected health information involves no more than minimal risk to the privacy
of individuals, based on at least the presence of all the following elements:
Is a Limited Data Set (see below list) being
used?

Yes

No

(If “Yes”, provide a copy of the executed Data Use
Agreement.
Data Use Agreement - An agreement into which the covered entity enters with the intended recipient of
a limited data set that establishes the ways in which the information in the limited data set may be used
and how it will be protected
Limited Data Set with Data Use Agreement
A data set that excludes the following direct identifiers can be considered a Limited Data
Names
Certificate/license #s
Postal address info (if other than city, town, state,
VIN and Serial #s, license plate #s
and ZIP)
Device identifiers, serial #s
Telephone and fax #s
Web URLs
E-mail address
IP address #s
Social Security #
Biometric identifiers (finger prints)
Medical record numbers
Full face photographic images and any comparable
Health plan #s
images
Account #s
The Limited Data Set CAN contain:
Elements of Dates i.e. Admission, Discharge, Service and Death Dates
City, Town, State and Zip Code(s)
Other unique identifiers, characteristics and codes not previously listed as direct identifiers
There is an adequate plan to protect the identifiers from improper use and disclosure. An adequate
plan to destroy the identifiers at the earliest opportunity consistent with conduct of research, unless
there is a health or research justification for retaining the identifiers or such retention is otherwise
required by law.
Describe your plan:
(continued)
APPLICATION (FULL BOARD)
and
Adequate written assurance that the protected health information will not be reused or disclosed to
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any other person or entity, except as required by law, for authorized oversight of the research study,
or for other research for which the use and disclosure of protected health information would be
permitted by this subpart.
Describe your plan:
or
The research could not practicably by conducted without the HIPAA waiver or alteration.
Provide explanation:
or
The research could not practicably by conducted without access to and use of the protected health
information.
Provide explanation:

List of Identifiers Related to PHI
Names
Geographic subdivisions smaller than a state
Zip Codes
Dates (birth, admission, discharge, death)
Age, if over 90
Telephone numbers
Fax numbers
E-mail addresses
Social Security numbers
Medical Record numbers
If PHI is being used and not part of a Limited
Data Set is the data going outside of CMHC?

Health plan beneficiary numbers
Account numbers
Certificate and license numbers
Vehicle identification and serial numbers
License plate numbers
Device identifiers and serial numbers
URLs
Internet Protocol address numbers
Biometric identifiers (finger and voice prints)
Full face photos and comparable images
Any other unique identifiers
Yes
No
(If “Yes”, please provide a copy of an executed Business Associate
Agreement.

(continued)
APPLICATION (FULL BOARD)

Identify Activities Preparatory to Research
For activities involved in preparing for research, covered entities may use or disclose PHI to a researcher
without an individual's Authorization, a waiver or an alteration of Authorization, or a Data Use
Agreement. However, the covered entity must obtain from a researcher representations that (1) the use or
disclosure is requested solely to review PHI as necessary to prepare a research protocol or for similar
purposes preparatory to research, (2) the PHI will not be removed from the covered entity in the course of
review, and (3) the PHI for which use or access is requested is necessary for the research. The covered
entity may permit the researcher to make these representations in written or oral form.
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Please describe this use and disclosure of PHI:
According to HHS guidance on the Privacy Rule, the preparatory to research provision permits covered
entities to use or disclose protected health information for purposes preparatory to research, such as to aid
study recruitment. However, the provision at 45 CFR 164.512(i)(1)(ii) does not permit the researcher to
remove protected health information from the covered entity's site. As such, a researcher who is an
employee or a member of the covered entity's workforce could use protected health information to contact
prospective research subjects [emphasis added]. The preparatory research provision would allow such a
researcher to identify prospective research participants for purposes of seeking their authorization to use
or disclose protected health information for a research study.
Yes, I agree to the above.

Signature

Date

Print Name

Title

continued)
APPLICATION (FULL BOARD)

FOR IRB USE ONLY
Is an Informed Consent Required?
Yes

No (Research meets all four CFR *ICF waiver criteria listed below)

Informed consent waiver criteria (check all that apply)
The research involves no more than minimal risk to the subjects,
The waiver or alteration will not adversely affect the rights and welfare of the subjects,
The research could not practicably be carried out without the waiver or alteration, and
Whenever appropriate, the subjects will be provided with additional pertinent information after
participation.
DETERMINATION
Informed Consent and HIPAA waiver criteria are met and Waiver of Authorization was approved
IRB Recommendation:
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This project is approved
This project is not approved; further details provided within IRB’s determination letter.

Certification: I have reviewed the above-captioned protocol for general scientific & medical validity
and safety.

Signature

Date

Print Name

Title

(continued)
APPLICATION (FULL BOARD)

IRB REVIEW FEE POLICY
It is a standard practice among Institutional Review Boards to charge a fee to commercial sponsors for
new studies reviewed by the full Board, new studies that can be reviewed as expedited and studies that are
up for a continuing review.
Effective January 2010, the IRB fees are as follows:
• $2,000.00 fee (increased from $1,750.00) for new studies reviewed by the full Board,
• $500.00 fee (no fee increase) for new expedited studies reviewed (protocols reviewed by a
single IRB reviewer),
• $250.00 fee (new fee) for all continuing reviews or amendments whether full Board or
Expedited.
These fees do not currently apply to non-funded, or federally-funded research. IRB initial review
applications will request sponsor billing information for the billing of these fees with an expectation that
the Study Coordinators/Principal Investigators will notify the IRB of any address changes for billing. The
IRB Administrator will forward a copy of the billing information to the Director of Research who will
process the bill with the sponsor. Once CMHC receives the IRB fee either the Director of Research or
Accounts Payable office will notify the IRB Administrator payment has been received. This fee is for
IRB review and is not contingent upon approval.
Upon notice by the Principal Investigator the IRB may waive this fee if the IRB finds the fee would create
a meaningful obstacle to research conduct.
Billing Contact Person Name:

Phone:

TRANEXAMIC ACID AND HIP FRACTURES
Sponsor Name:
Sponsor Mailing Address:

IRB#:
Protocol Entitled [as given above]:
Account No:
Billing Information:
Fee for IRB processing of Principal Investigator:

For office Use:
Full Board: ($2,000.00)
Expedited: ($500)
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October 16, 2016
Dear Institutional Review Board Committee Members,
This letter is to inform you that no conflict of interest exists between Kate Balzano-Cowan and Morgan
Guerrette regarding our involvement with the project: Utilizing Tranexamic Acid to Reduce Blood Transfusion in
Hip Fractures. No promises of profit or advantage were made from Central Maine Medical Center for the work
provided to this project. Additionally, participation in this project does not guarantee a positive outcome or passing
grade from the University of New England concerning our Senior Capstone Project or other classroom work.
Sincerely,
Morgan Guerrette and Kate Balzano-Cowan
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TRANEXAMIC	
  ACID	
  PATIENT	
  INFORMATION	
  
	
  
	
  
	
  

WHAT	
  IS	
  TRANEXAMIC	
  ACID?	
  
Tranexamic	
  acid	
  (TXA)	
  is	
  given	
  through	
  an	
  IV	
  to	
  prevent	
  or	
  reduce	
  bleeding	
  and	
  reduce	
  the	
  
need	
  for	
  blood	
  transfusions	
  during	
  a	
  trauma	
  or	
  surgery.	
  	
  	
  
	
  

WHY	
  IS	
  THIS	
  STUDY	
  BEING	
  DONE?	
  

This	
   research	
   is	
   being	
   done	
   because	
   we	
   have	
   seen	
   excellent	
   results	
   using	
   tranexamic	
   acid	
  
during	
   scheduled	
   hip	
   and	
   knee	
   replacements.	
   	
   Research	
   has	
   shown	
   patients	
   receiving	
  
tranexamic	
  acid	
  before	
  scheduled	
  surgery	
  to	
  replace	
  hip	
  and	
  knee	
  joints	
  bleed	
  less.	
  	
  We	
  hope	
  
that	
  using	
  this	
  drug	
  in	
  traumatic	
  hip	
  fractures	
  will	
  give	
  patients	
  the	
  same	
  benefit.	
  
	
  

ARE	
  THERE	
  BENEFITS	
  TO	
  TRANEXAMIC	
  ACID?	
  

Tranexamic	
  acid	
  has	
  been	
  shown	
  in	
  other	
  research	
  to	
  reduce	
  bleeding	
  and	
  the	
  need	
  to	
  be	
  given	
  
blood	
   from	
   another	
   person	
   after	
   traumatic	
   accidents	
   and	
   before	
   planned	
   hip	
   and	
   knee	
  
replacement	
  surgeries.	
  
	
  

ARE	
  THERE	
  RISKS	
  AND	
  SIDE	
  EFFECTS	
  OF	
  TRANEXAMIC	
  ACID?	
  

Risks	
  and	
  side	
  effects	
  related	
  to	
  giving	
  tranexamic	
  acid	
  to	
  reduce	
  blood	
  loss	
  might	
  include:	
  
Adverse	
  vascular	
  event	
  including,	
  but	
  are	
  not	
  limited	
  to,	
  myocardial	
  infarction	
  (very	
  rare	
  but	
  
serious),	
  symptomatic	
  DVT	
  (less	
  likely	
  but	
  serious),	
  or	
  pulmonary	
  embolism	
  (less	
  likely	
  but	
  
serious).	
  
	
  
	
  
For	
  more	
  information	
  about	
  risks	
  and	
  side	
  effects,	
  and/or	
  to	
  report	
  side	
  effects	
  and	
  adverse	
  
events.	
   	
   Please	
   speak	
   to	
   the	
   researcher	
   or	
   contact	
   Elizabeth	
   Turcotte,	
   RN	
   via	
   phone	
  
(207.795.2134)	
  or	
  email	
  (TurcotEl@cmhc.org).	
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TXA: Current Uses

TXA Fracture Study
January 2017
CMMC-OICM-CMO-UNE

• Total knee replacements
• Total hip replacements
• Literature demonstrates TXA reduces blood product
utilization
• Nationally being widely utilized for traumas etc...
• CRASH-2 STUDY

TXA: Hip Fracture Study

Inclusion/Exclusion Criteria

• GOAL: to see a decrease in blood utilization and
better outcomes for patients with hip fracture

Inclusion Criteria:

• Starting January 11, 2017

•

•

Exclusion Criteria:

Any patient over age 50 with •
hip fracture
•
Gives consent to participate in
the study

• Patients with fractured hips can be entered into TXA
study
• Each patient receives a hospitalist consult
• Based on patient history they can either be included
in the study or excluded

•

Anticoagulated
History of vascular events:
o stroke
o myocardial infarction
o pulmonary embolism
o deep vein thrombosis
o clotting disorder
Patients with either unknown
or if a full medical history can
not be obtained

1

TRANEXAMIC ACID AND HIP FRACTURES

60

2/2/17

Process
• Patient receives hospitalist consult at admission

• Determined to be either potential inclusion or ruled
an exclusion

Consents
• Patients selected as “meets criteria” for inclusion:
• Patient/POA will be educated - literature and
discussion about what is TXA, risks, benefits
• If they choose to enroll in the study - consent will be
obtained

• Patient will receive a packet and face to face time to
complete the informed consent

Who orders the drug?
• Ideally the surgeon will order the drug
• The drug is ordered by entering the words “study
drug”
• If the surgeon is not able to order the drug, the
Clinical Coordinator or the CRNA will order the
drug as a verbal order under the surgeon
• The pharmacy will send the “study drug” as an on
call medication when the patient is going to the OR

• “Study drug” will be ordered and patient will receive
either TXA or placebo

Who gets Consents
• Consents can only be obtained by those who are
listed on the IRB application
• Surgeons CMO/Clinical Coordinators M2/Jim
Osgood or Tina Moring/Morgan Guerrette or Kate
Balzano-Cowan
• Primarily Clinical Coordinators during weekday
hours
• Jim Osgood or Tina Moring on weekend hours

2
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What do we need to know?
• Starting in 2017 TXA for fractured hips may be given –
“Study Drug”
• It is a one time dose much like TXA for total hips now
• Sign off on the MAR as “study drug”
• Either TXA or Placebo drug will be administered
• Providers (surgeons, nurse, CRNA) will be blinded as to
what the patient has received either TXA or placebo

Post Op
• Post op patients will be entered into a data base and
tracked for blood product utilization and/or
complications
• Data will be followed for approximately 1 year
• Communicate with PACU/Post op team that patient
was enrolled in the “study”
• Goals: see a decrease in blood product utilization
and better outcomes for patients with hip fracture

3
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Appendix D
Informed Consent

Central Maine Healthcare Corporation
Authorization to Participate in a Research Project
STUDY TITLE: Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures
IRB NUMBER: 494
CONSENT VERSION DATE: 10.09.2016
HOSPITAL OR INSTITUTION: Central Maine Medical Center
INVESTIGATOR: Morgan Guerrette
SUBJECT’S NAME (printed):

You are being asked to volunteer for a research study. Research studies include only patients who choose
to take part. In order to decide whether you should agree to be part of this research study, you should
understand enough about its risks and benefits to make an informed choice. This process is known as
informed consent. Please take your time to make your decision. If we are unable to obtain a full medical
history, you will be excluded from this study.
You are being asked to take part in this study because you have sustained a traumatic fracture to one of
your hip joints.
WHY IS THIS STUDY BEING DONE?

This research is being done because we have seen excellent results using tranexamic acid during
scheduled hip and knee replacements. Research has shown patients receiving tranexamic acid before
scheduled surgery to replace hip and knee joints bleed less. We hope that using this drug in traumatic hip
fractures will give patients the same benefit.
HOW MANY PEOPLE WILL TAKE PART IN THE CLINICAL TRIAL?
Up to 125 people will take part in this study. Central Maine Medical Center is the only site approved to
enroll people into this study.
WHAT IS INVOLVED IN THE STUDY?
If you decide you would like to participate in this study, you will be “randomized” into one of the study
groups described below. Randomization means that you are put into a group by chance. It is like flipping
a coin. A computer decides which group you are put in. Neither you nor the researcher will choose what
group you will be in. You will have an equal chance of being placed in any one group. The groups are:
The control group or the drug-receiving group. Patients in the control group will be treated in the same
way as all patients coming to the hospital with broken hips are presently treated. Patients in the control
group will not receive tranexamic acid before having surgery to repair their broken hip. Patients in the
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drug-receiving group will be given 1gram of tranexamic acid before having surgery to repair their broken
hip.

•

Standard procedures and tests that will be done during the trial which are part of the regular care of a
patient with a hip fracture are complete blood counts done the day of your surgery and at regular intervals
after surgery as determined by your doctor.

•

There are no additional standard procedures or tests that will be done during the trial that are being done
because of participation in the trial.

•

Should you be randomized into the drug-receiving group, giving you the tranexamic acid prior to your hip
surgery is the only procedure/test that is considered experimental and being tested in this trial.
HOW LONG WILL I BE IN THE STUDY?
We think you will be in the study for the length of your admission to the hospital to have your broken hip
fixed.
Should you decide to take part in this study, there is no reason the researcher may decide to take you off
this study.
You can stop participating at any time. However, if you decide to stop participating in the study, we
encourage you to talk to the researcher and your regular doctor first. There are no serious consequences
of sudden withdrawal from the study and there are no additional testing or procedures that would need to
be done in order for you to safely withdraw from this study.
WHAT ARE THE RISKS OF THE STUDY?
While in this study, you are at risk for these side effects listed below. You should discuss these with the
researcher and/or your regular doctor. There also may be other side effects that we cannot predict; in
some cases side effects can be serious or long lasting or permanent.
Risks and side effects related to giving tranexamic acid to reduce blood loss might include:
Adverse vascular event including, but are not limited to, myocardial infarction (very rare but serious),
symptomatic DVT (less likely but serious), or pulmonary embolism (less likely but serious).
For more information about risks and side effects, and/or to report side effects and adverse events speak
to the researcher or contact Elizabeth Turcotte, RN via phone (207.795.2134) or email
(TurcotEl@cmhc.org).
ARE THERE BENEFITS TO TAKING PART IN THE CLINICAL TRIAL?
You may benefit from the being given tranexamic acid prior to your hip surgery provided to you by this
research. Tranexamic acid has been shown in other research to reduce bleeding and the need to be given
blood from another person after traumatic accidents and before planned hip and knee replacement
surgeries.
WHAT OTHER OPTIONS ARE THERE?
Instead of being in this study, you have the option to decline and will be treated in the same way as
patients randomized into the control group of this study.
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Please talk to your regular doctor about these and other options.
WHAT ABOUT CONFIDENTIALITY?
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute
confidentiality. Your personal information may be disclosed if required by law. All of your personal and
medical data will be handled in the same way all other personal and medical data at Central Maine
Medical Center is handled. Your agreement to take part in this study does not mean you agree to have
your personal information disclosed. If you choose to withdraw from the study, you may revoke your
approval for the use of your future medical information. To do this, you may contact the researcher in
writing. Data which has already been collected, will be maintained with the research records. Study
information collected up to that point will be forwarded to the study sponsor. No further study
information will be collected after you withdraw from the study.
WHAT ARE THE COSTS?
You or your insurance company will not be charged for any tests or services specifically required by this
research study unless the tests or services are clinically indicated or part of your standard treatment. You
will still be responsible for the cost of your usual ongoing medical care, including procedures, non-study
medications, and tests that your study doctor or regular doctor requires during this study as part of your
usual medical care.
In the case of injury or illness resulting from this clinical trial, emergency medical treatment is available,
but will be provided at the usual charge. Central Maine Medical Center will not compensate you or your
insurance company in the event of any injury.
Central Maine Medical Center is not being compensated for their participation in this research study by
the study.
WHAT ARE MY RIGHTS AS A PARTICIPANT?
Taking part in this study is your choice. You may choose not to take part or may leave the study at any
time. Leaving the study will not result in any penalty or loss of benefits to which you are entitled.
We will tell you about new information that may affect your willingness to stay in this study.
PERMISSION TO USE OR RELEASE IDENTIFIABLE HEALTH INFORMATION
FOR RESEARCH PURPOSES
WHY AM I BEING ASKED TO RELEASE THIS INFORMATION?

As part of this clinical trial, you are being asked to allow Morgan Guerrette to collect health
information about yourself. This information will be collected, entered onto a database with the
health information from others taking part in this clinical trial, and studied to see if giving
tranexamic acid before surgery to patients who have broken their hip in a fall lowers their need to
be given blood products from other people. Morgan Guerrette may also need to obtain copies of
any medical records you have with other health care providers.
WHAT AM I BEING ASKED TO RELEASE?
For this clinical trial, the following information will be collected:

Your date of birth

Your past medical history

Your weight, blood pressure, temperature, lab results, and the results of your physical
examination during your admission to Central Maine Medical Center to get your broken
hip fixed.
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WHO WILL SEE THIS INFORMATION?
Personnel or members of the Central Maine Medical Center Institutional Review Board or
personnel from the Office of Human Research Protections may see parts of your medical records
related to this clinical trial and, therefore, will see your name and other personally identifiable
information about you. The information collected is the property of Morgan Guerrette, and you
will not be able to get it back.
WILL THE INFORMATION COLLECTED AS PART OF THIS STUDY BE DESTROYED WHEN IT IS NO LONGER NEEDED?

In the event of any publication regarding this study, your identity will not be disclosed. It is
difficult for Morgan Guerrette to know how long your information will be kept at least until the
end of the clinical trial, but most likely it will be kept on a database within the Anesthesia
Department at Central Maine Medical Center for an indefinite length of time. We do not know
when your information will no longer be used, and there is not expiration date after which it will
be discarded.
CAN I STOP MY INFORMATION FROM BEING USED?
If you choose to withdraw from the study, you may revoke your approval for the use of your future
medical information. To do this, you may contact the researcher in writing. Data that has already been
collected will be maintained with the research records. Study information collected up to that point would
be forwarded to the study sponsor. No further study information will be collected after you withdraw
from the study.
During the study, you may not have access to your information through the researcher but you may
request information after research is completed. All information collected as part of this study will be
part of your medical record at Central Maine Medical Center. Should you wish to obtain your
information through the hospital please contact Medical Records Department and follow their
instructions.
WHAT IF I DO NOT AUTHORIZE YOU TO COLLECT AND RELEASE MY HEALTH INFORMATION?

If you agree to be in this clinical trial, you are authorizing the release of your health information as part of
the trial. Participants will be given a copy of the signed consent document for their own records. If you
do not want to release your health information, you may not want to take part in this clinical trial (do not
sign this form if you do not want to take part in this clinical trial, or you do not want to release your
health information).
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
For questions about the study or a research-related injury contact Elizabeth Turcotte via phone
(207.795.2134) or email (TurcotEl@cmhc.org).
For questions about your rights as a research participant, contact the Central Maine Medical Center
Institutional Review Board (which is a group of people who review the research to protect your rights) at
(207) 795-2176. Deborah Taylor, Ph.D. is the chairperson of the Central Maine Medical Center
Institutional Review Board.
COMPENSATION
Participants in this study will not receive any compensation if the results of the research are used towards
the development of a commercially available product.
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A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by
U.S. Law. This Web site will not include information that can identify you. At most, the Web site
will include a summary of the results. You can search this site at any time pursuant to 21 CFR
50.25(C). For applicable clinical trials as defined in 42 U.S.C. 282(j)(1)(A).

You have read, or have had read to you, the above information before signing this consent form. You agree to
participate in this clinical trial. You also authorize you your permission to use or disclose your personal health
information for the purpose of this research. You have been offered ample opportunity to ask questions and have
received answers that fully satisfy those questions.

I have agreed to participate in this research project. I understand the purpose of the procedure(s) and the
risks/benefits involved in its performance.

________________________________________
Signature of Participant or guardian

_________________
Date

________________________________________

Printed Name of Participant or guardian

I have fully explained to _________________the nature and purpose of the above-described procedure
and the risks/benefits involved in its performance. I have answered and will answer all questions to the
best of my ability. I will inform the subject of any changes in the procedure or the risks and benefits if
any should occur during or after the course of the study.
___________________________________________
Signature of person obtaining consent

_________________
Date
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